Biodexa Pharmaceuticals Files 6-K, Furnishes Exhibit 99.1
Ticker: BDRX · Form: 6-K · Filed: Apr 17, 2025 · CIK: 1643918
| Field | Detail |
|---|---|
| Company | Biodexa Pharmaceuticals PLC (BDRX) |
| Form Type | 6-K |
| Filed Date | Apr 17, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, sec-filing, foreign-private-issuer
Related Tickers: BDRX
TL;DR
Biodexa Pharmaceuticals (BDRX) filed a 6-K on 4/17/25, furnishing an exhibit; standard reporting update.
AI Summary
Biodexa Pharmaceuticals PLC filed a Form 6-K on April 17, 2025, to report information as a foreign private issuer. The filing indicates that the company will file annual reports under Form 20-F. The document includes Exhibit 99.1, which is being furnished and not deemed filed for purposes of Section 18 of the Exchange Act.
Why It Matters
This filing provides routine updates for investors and regulators regarding Biodexa Pharmaceuticals' reporting status and furnished information, ensuring transparency for stakeholders.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily furnishes information and confirms reporting status, not indicating new material events or financial changes.
Key Players & Entities
- Biodexa Pharmaceuticals PLC (company) — Filer of the 6-K report
- April 17, 2025 (date) — Filing date of the Form 6-K
- Form 20-F (document) — Annual report form the company will file
- Exhibit 99.1 (document) — Furnished information within the filing
- Section 18 of the Securities Exchange Act of 1934 (legal_document) — Information furnished is not subject to liabilities under this section
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers filed with the SEC to provide information that the issuer would be required to disclose to its security holders or make public pursuant to the laws of its home country or a foreign stock exchange.
What does it mean that Exhibit 99.1 is being 'furnished' and not 'filed'?
When information is furnished, it is provided to the SEC but is not deemed 'filed' for the purposes of Section 18 of the Exchange Act, meaning the company is not subject to the liabilities associated with filed documents under that section.
Which annual report form will Biodexa Pharmaceuticals PLC file?
Biodexa Pharmaceuticals PLC will file its annual reports under cover of Form 20-F.
What is the principal executive office address of Biodexa Pharmaceuticals PLC?
The principal executive office is located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom.
What is the Commission File Number for Biodexa Pharmaceuticals PLC?
The Commission File Number for Biodexa Pharmaceuticals PLC is 001-37652.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 17, 2025 regarding Biodexa Pharmaceuticals Plc (BDRX).